← ANALYST RATINGS · TIPRANKS
Xencor (XNCR): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy1 Hold0 Sell
Ratings of 10 analysts in the last 3 months · top analysts only12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $32.00, the highest $46.00, the lowest $20.00. The average is +40.0% from the last price of $22.85.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $24.50 → $25.00+2.0% | Hold | +9.4% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.00 → $23.50+2.2% | Hold | +2.8% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $24.50 → $25.00+2.0% | Hold | +9.4% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.50 → $24.00+2.1% | Hold | +5.0% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.50 → $24.00+2.1% | Hold | +5.0% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $20.00 | Buy | −12.5% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $30.00 | Buy | +31.3% | Reiterated | 15.10.26on TipRanks 07:55 | +2.3%next day −3.7% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $26.00 → $25.00−3.8% | Hold | +9.4% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| Unknown Analyst | Wells Fargo | $30.00 | Buy | +31.3% | Reiterated | 29.09.26on TipRanks Oct 1 00:06 | −2.2%next day 0.0% · 5 days −4.5% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $27.00 → $29.00+7.4% | Buy | +26.9% | Reiterated | 28.09.26on TipRanks 07:30 | +8.3%next day −2.2% · 5 days −1.1% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $30.00 | Buy | +31.3% | Reiterated | 25.09.26on TipRanks 09:45 | −0.9%next day +8.3% · 5 days +4.6% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $26.00 | Hold | +13.8% | Reiterated | 21.09.26on TipRanks 06:45 | −0.3%next day +0.5% · 5 days +3.3% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $27.00 → $35.00+29.6% | Buy | +53.2% | Reiterated | 11.09.26on TipRanks 05:15 | −0.2%next day +0.9% · 5 days +1.4% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $14.00 → $21.00+50.0% | Hold | −8.1% | Reiterated | 03.09.26on TipRanks 09:30 | −2.1%next day +0.3% · 5 days −7.2% | ↗ |
| Sean McCutcheon★★★★★★★★★★#1382 · hits 43% · avg +39.7% | Raymond James | $46.00 | Buy | +101.3% | Assigned | 01.09.26on TipRanks 07:20 | +3.1%next day −4.1% · 5 days −10.7% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $44.00 | Buy | +92.6% | Reiterated | 10.08.26on TipRanks 07:45 | +3.7%next day +2.7% · 5 days +7.2% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $33.00 | Buy | +44.4% | Reiterated | 06.08.26on TipRanks 07:01 | +1.0%next day +3.4% · 5 days +13.7% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 01:19 | +1.0%next day +3.4% · 5 days +13.7% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $38.00 | Buy | +66.3% | Reiterated | 05.08.26on TipRanks Aug 6 09:35 | −0.2%next day +1.0% · 5 days +16.5% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Buy | — | Reiterated | 05.08.26on TipRanks Aug 6 06:00 | −0.2%next day +1.0% · 5 days +16.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Xencor
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $32.00 at a price of $24.95 (+28.3%); now: $32.00 at $22.85 (+40.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 5 | 6 | 6 | 5 |
| Buy | 3 | 2 | 6 | 8 | 11 | 9 |
| Hold | 2 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.38 (from $-1.21 to $0.22). Last quarter: $-0.29.
Sales
Next quarter’s sales estimate — $59M (from $3M to $115M). Last quarter: $51M.
Best top-analyst consensus in the sector · Healthcare
About Xencor
- CEO: Bassil I. Dahiyat
- Employees: 260
- 465 North Halstead Street, Pasadena, CA, 91107, US
- www.xencor.com
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensin
Data from the stock’s TipRanks forecast page, read 9 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗